Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

29

Revenue 2017

Soliris

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Soliris was produced by Alexion.

Alnylam swaps Sanofi for Regeneron as R&D partner

Alnylam swaps Sanofi for Regeneron as R&D partner C5 is also targeted by Alexion’s Soliris (eculizumab) for paroxysmal nocturnal hemoglobinuria (PNH) and haemolytic uremic syndrome (HUS), which was a $2.56bn product last year.

Drug launches to watch in 2019

Drug launches to watch in 2019 Analysts predict peak sales of up to $3bn. 5. Ultomiris – Alexion’s follow-up to Soliris. ... The drug matched Soliris for efficacy with a trend towards superiority and has improved dosing.

Alexion targets RNAi with $637m Dicerna deal

Alexion targets RNAi with $637m Dicerna deal Alexion already has a follow-on complement inhibitor to be the next generation replacement for Soliris. ... With Soliris, Alexion has demonstrated the transformative impact of complement inhibition on multiple serious and debilitating diseases.

Alexion adds to pipeline with $1.2bn Syntimmune buy

Alexion adds to pipeline with $1.2bn Syntimmune buy Alexion is in the midst of a concerted effort to build its pipeline as it prepares for the possible loss of patent protection for Soliris (eculizumab), its biggest-selling product. ... Used to treat paroxysmal nocturnal haemoglobinuria (PNH) and

The year of the blockbuster

The year of the blockbuster These include Juno Therapeutics’ CAR T-cell therapy, lisocabtagene maraleucel, for diffuse large B-cell lymphoma, and Alexion’s next-generation Soliris treatment, ravulizumab, for paroxysmal nocturnal haemoglobinuria.

[ Previous 5 results ] 1 2 3 4 5 6 7 8 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...
PANDAS/PANS Awareness: A parent’s story
To help raise awareness of these often underdiagnosed diseases, Jon Hallows, Joint MD at Porterhouse shares his own experience as a parent of a son recently diagnosed with PANDAS...

Infographics